Strs Ohio Aldeyra Therapeutics, Inc. Transaction History

Strs Ohio

$23.2 Billion
Q1 2025

A detailed history of Strs Ohio transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Strs Ohio holds 76,500 shares of ALDX stock, worth $328,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,500

Previous 97,900 21.86%

Holding current value

$328,950

Previous $527,000 16.7%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 28, 2025	SELL	$4.7 - $6.98 $100,580 - $149,372	-21,400 Reduced 21.86%	76,500 $439,000
Q4 2024 May 28, 2025	BUY	$4.21 - $5.9 $90,094 - $126,260	21,400 Added 27.97%	97,900 $488,000
Q3 2024 Nov 01, 2024	BUY	$3.19 - $6.32 $19,778 - $39,184	6,200 Added 6.76%	97,900 $527,000
Q2 2024 Aug 05, 2024	BUY	$3.25 - $4.72 $30,550 - $44,368	9,400 Added 11.42%	91,700 $303,000
Q1 2024 May 13, 2024	SELL	$2.77 - $4.22 $14,404 - $21,944	-5,200 Reduced 5.94%	82,300 $269,000
Q4 2023 Jan 30, 2024	BUY	$1.47 - $6.06 $93,933 - $387,234	63,900 Added 270.76%	87,500 $307,000
Q2 2023 Jul 31, 2023	BUY	$7.11 - $11.89 $167,796 - $280,604	23,600 New	23,600 $198,000
Q2 2020 Jul 23, 2020	SELL	$1.97 - $5.05 $58,509 - $149,985	-29,700 Closed	0 $0
Q3 2019 Oct 21, 2019	SELL	$4.41 - $6.12 $186,102 - $258,264	-42,200 Reduced 58.69%	29,700 $156,000
Q2 2019 Jul 25, 2019	BUY	$6.0 - $9.0 $30,000 - $45,000	5,000 Added 7.47%	71,900 $431,000
Q1 2019 Apr 19, 2019	BUY	$7.14 - $9.85 $200,634 - $276,785	28,100 Added 72.42%	66,900 $604,000
Q4 2018 Jan 23, 2019	BUY	$7.26 - $13.29 $247,566 - $453,189	34,100 Added 725.53%	38,800 $322,000
Q2 2018 Aug 06, 2018	BUY	$6.95 - $9.18 $32,665 - $43,146	4,700 New	4,700 $37,000

Others Institutions Holding ALDX

# of Institutions

139

Shares Held

38.6M

Call Options Held

620K

Put Options Held

435K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $251M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account